Table 4.
Subsequent treatment
| GP (n=139) | IP (n=140) | p-value | |
|---|---|---|---|
| Second-line therapy | |||
| Pemetrexed | 40 (28.8) | 39 (27.9) | 0.189 |
| Docetaxel | 35 (25.2) | 51 (36.4) | |
| EGFR-TKI | 34 (24.5) | 33 (23.6) | |
| Platinum-based doublet | 2 (1.4) | 3 (2.1) | |
| Crizotinib | 2 (1.4) | 1 (0.7) | |
| No treatment | 26 (18.7) | 13 (9.3) | |
| Third-line therapy | |||
| Pemetrexed | 38 (27.3) | 46 (32.9) | 0.428 |
| Docetaxel | 15 (10.8) | 16 (11.4) | |
| EGFR-TKI | 31 (22.3) | 26 (18.6) | |
| Doublet chemotherapy | 8 (5.8) | 14 (10.0) | |
| ALK-TKI | 2 (1.4) | 1 (0.7) | |
| Radiotherapy | 2 (1.4) | 3 (2.1) | |
| Anti-PD1 therapy | 0 | 2 (1.4) | |
| No treatment | 43 (30.9) | 32 (22.9) |
Values are presented as number (%). GP, gemcitabine and cisplatin; IP, irinotecan and cisplatin; EGFR, epidermal growth factor receptor; TKI, tyrosine kinase inhibitor; ALK, anaplastic lymphoma kinase.